Merck & Co. , Inc. operates in the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Merck & Co. with three other companies in this sector in UNITED STATES : Abbvie Inc (2020 sales of $45.80 billion of which 100% was pharmaceutical products), Bristol-Myers Squibb Company ($42.52 billion of which 28% was Prioritized Brands-Revlimid), and Pfizer Inc. ($41.91 billion of which 26% was Oncology).

Sales Analysis. During the second quarter of 2021, sales at Merck & Co. totalled $11.40 billion. This is an increase of 4.9% from the $10.87 billion in sales at the company during the second quarter of 2020. During the first two quarters of 2021, sales totalled $22.03 billion, which is 3.9% lower than through the first two quarters of 2020. Merck & Co. reported sales of $47.99 billion for the year ending December of 2020. This represents an increase of 2.5% versus 2019, when the company's sales were $46.84 billion. Sales at Merck & Co. have increased during each of the previous five years (and since 2015, sales have increased a total of 22%). Sales of Animal Healthcare saw an increase that was more than double the company's growth rate: sales were up 7.1% in 2020, from $4.39 billion to $4.70 billion. Not all segments of Merck & Co. experienced an increase in sales in 2020: sales of All Other fell 86.9% to $23.00 million. (However, this segment's sales were only a very small portion of the company's overall sales). Merck & Co. also experienced decreases in sales in Unallocated (down 52.6% to $247.00 million) .